Previous Article | Next Article 
Infection and Immunity, May 2001, p. 3073-3081, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.3073-3081.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Reversal of the CD4+/CD8+
T-Cell Ratio in Lymph Node Cells upon In Vitro Mitogenic Stimulation by
Highly Purified, Water-Soluble S3-S4 Dimer of Pertussis
Toxin
Rauf
Latif,1,
Nicole Kerlero
de Rosbo,1
Tany
Amarant,2
Rino
Rappuoli,3
Gregor
Sappler,1 and
Avraham
Ben-Nun1,*
Department of Immunology, The Weizmann
Institute of Science,1 and
ProSpec-TechnoGene, Weizmann Science
Park,2 Rehovot, Israel, and
Immunobiological Research Institute Siena (IRIS), 53100 Siena,
Italy3
Received 1 December 2000/Returned for modification 4 January
2001/Accepted 19 February 2001
 |
ABSTRACT |
Pertussis toxin (PT), a holomer consisting of a catalytic S1
subunit and a B oligomer composed of S2-S4 and S3-S4 dimers, held
together by the S5 subunit, exerts profound effects on immune cells,
including T-cell mitogenicity. While the mitogenic activity of PT was
shown to reside fully within the B oligomer, it could not be assigned
to any particular B-oligomer component. In this study, we purified the
S3-S4 dimer to homogeneity under conditions propitious to maintenance
of the native conformation. In contrast to previous reports which
suggested that both S3-S4 and S2-S4 dimers are necessary for mitogenic
activity, our preparation of the highly purified S3-S4 dimer was as
strongly mitogenic as the B oligomer, suggesting that the S3-S4 dimer
accounts for the mitogenic activity of the B oligomer. Moreover, in
vitro stimulation of naive lymphocytes by the S3-S4 dimer resulted in
reversal of the normal CD4+/CD8+ T-cell ratio
from approximately 2:1 to 1:2. The reversal of the CD4+/CD8+ T-cell ratio is unlikely to be due to
preferential apoptosis-necrosis of CD4+ T cells, as
indicated by fluorescence-activated cell sorter analysis of
annexin-stained T-cell subsets, or to preferential stimulation of
CD8+ T cells. The mechanism underlying the reversal
requires further investigation. Nevertheless, the data presented
indicate that the S3-S4 dimer may have potential use in the context of
diseases amenable to immunological modulation.
 |
INTRODUCTION |
Pertussis toxin (PT), the major
virulence determinant of Bordetella pertussis
(35), is composed of two distinct functional units, the A
protomer, consisting of a single polypeptide (S1) which mediates
adenosine diphosphate ribosylation of host G proteins, and the B
oligomer, which mediates the binding of the toxin to host cells and the
translocation of toxic S1 to its target (8, 28). The B
oligomer is a complex pentamer composed of subunits S2, S3, S4, and S5
in a respective molar ratio of 1:1:2:1, with S2 and S3 occuring as
heterodimers each with S4, i.e., dimer S2-S4 and dimer S3-S4, held
together by S5 (28, 32). The effects of the toxin on cells
of the immune system are multiple and include induction of
lymphocytosis, inhibition of macrophage migration, adjuvant activity,
and T-cell mitogenicity (18). A number of the biological
activities of PT, such as lymphocytosis and adjuvant activity,
implicate the enzymatic activity of PT in its toxicity and can be
abrogated by inactivation of the S1 subunit (1, 5, 13). In
contrast, PT-associated T-cell mitogenicity is mediated by the B
oligomer (9, 31, 36) and appears to be independent of the
enzymatic activity of the toxin, as inactivation of the S1 subunit by
mutation has no effect on the mitogenic activity of PT (13,
36), while alterations in the B oligomer can totally abrogate
the mitogenic activity of PT (15, 16, 20-22). In
addition, the B oligomer devoid of S1 induces T-cell proliferation to
the same extent as PT (22, 29, 31, 32, 36). However,
although the mitogenic effect of the B oligomer is well known, the
roles of its individual components in the mitogenic function have not been extensively studied. Both dimers have been implicated in the
binding of PT to cells via interaction of the B oligomer with glycoproteins and glycolipids on many types of
eukaryotic cells (10, 26, 37), seemingly via
carbohydrate-recognizing domains on subunits S2 and S3 (11, 26,
34, 37). However, there is evidence of a difference between the
binding specificities of the two dimers (26, 37), which
may account for observations leading to the suggestion that the B
oligomer must bind to the cell surface to permit translocation of the A
protomer into the cell in a manner different from its binding leading
to T-cell mitogenicity, since these two types of binding displayed
different susceptibilities to chemical modification of the molecule
(22; see Discussion). Experiments with hybrid PTs composed
of various combinations of chemically modified dimers indicate a
differential role of the two dimers in T-cell stimulation and suggest
that the S3-S4 dimer is more relevant to the binding of the B oligomer which results in T-cell stimulation than to the binding which results
in translocation of the S1 subunit (20-22). A mitogenic effect for the S3-S4 dimer as an isolated dimeric molecule was not demonstrated.
We have been investigating PT as an immunomodulatory agent for
experimental autoimmune encephalomyelitis (EAE), the well-accepted animal model for multiple sclerosis, and found that the protective effect imparted by PT against EAE could be fully attributed to the B
oligomer (3). To understand the mechanism by which the B
oligomer immunomodulates EAE, the role of its components in the
biological activity of the B oligomer should be investigated.
In the B oligomer, S2 and S3 occur naturally as parts of heterodimers,
each with S4. These dimers can only be dissociated into monomers under
strong denaturing conditions, suggesting that the dimeric conformation
is functionally important. Isolation of functional dimers is necessary
if we are to investigate their role in the biological activities of the
B oligomer. We have now purified the S3-S4 dimer to homogeneity under
conditions which favor preservation of the native conformation and
investigated its biological activity in vitro. We show that the S3-S4
dimer is as strong a mitogen for T cells as is the B oligomer, in
contrast to previous reports suggesting that a combination of S2-S4 and S3-S4 dimers is absolutely necessary to induce T-cell proliferation and
that neither dimer is mitogenic by itself (31, 36). The heterodimeric molecule appears to be essential for the mitogenic activity, as recombinant preparations of individual subunits could not
significantly induce T-cell proliferation. Most striking was the in
vitro modulatory effect of the purified S3-S4 dimer, as well as that of
the B oligomer, in reversing the CD4+/CD8+
T-cell ratio upon stimulation of naive lymph node (LN) cells.
 |
MATERIALS AND METHODS |
PT and recombinant subunits.
PT was obtained commercially
(catalog no. P 9452; Sigma, St. Louis, Mo.). Mutant PT (PTmu), a
genetically derived mutant of PT, PTX-9K/129G, was prepared as
described previously (24). This mutant contains two amino
acid substitutions, Arg9 with Lys and Glu129
with Gly, in the S1 subunit which abolish its enzymatic activity (24); the B oligomer is unaffected, and PTmu retains its
mitogenic activity (13; this study). The DNAs
corresponding to PT subunits S2, S3, and S4 cloned into expression
vector pEx31 or pEx34 (19) were subcloned into expression
vector pRSET (Invitrogen Corporation, San Diego, Calif.) after
amplification by PCR using specific primers in which NheI
and BamHI restriction sites or NheI and
BglII restriction sites had been included to enable ligation
at the 5' and 3' ends of S2 and S4 or S3, respectively. The primers
used were as follows: 5' S2 primer,
CATGGTATGGCTAGCACGCCAGGCATCGTCATTCCG; 3' S2 primer, GCAGCCGGATCCTCAGCATAAGGATGATCCAGGATT; 5' S4 primer,
CATGGTATGGCTAGCGACGTTCCTTATGTGCTG; 3' S4 primer,
GAGCTCGGATCCTCAGGGGCACTGCTTGCCGCT; 5' S3 primer, CATGGTATGGCTAGCGTTGCGCCAGGCATCGTCATC; 3' S3 primer,
TGAGCTCAGATCTCAGCATATCGACGCTGCCGGGTT. The nucleotide sequence of
the PCR product within each construct was confirmed by direct
sequencing using primers derived from pRSET (forward primer,
5'-ATGCGGGGTTCTCATCAT-3'; reverse primer, 5'-TAGCAGCCGGATCAAGCT-3') and a 373A DNA sequencer (Applied
Biosystems, Foster City, Calif.). The DNA sequences obtained confirmed
for each construct an open reading frame for the relevant subunit, preceded by (Met)-Arg-Gly-Ser-(His)6-Gly-Met-Ala-Ser.
Expression of the recombinant subunits was induced in the host
Escherichia coli BL21(DE3) (catalog no. C6000-03; Invitrogen
Corporation), and the recombinant protein was purified to homogeneity
by metal chelate affinity chromatography on Ni2+
nitrilotriacetic acid-agarose (catalog no. 30230; Qiagen, Chatsworth, Calif.) according to the manufacturer's protocol.
Preparation of antisera against PT and recombinant subunits.
Antisera against PT and the recombinant S2 subunit (rS2) were prepared
in SJL/J mice by subcutaneous injection of PT (500 ng of PT in
incomplete Freund adjuvant) or purified rS2 (50 µg of rS2 in complete
Freund adjuvant), followed by two booster injections of 25 µg of rS2
administered subcutaneously at weekly intervals in the flank. The
anti-PT serum which reacts predominantly with the S1 subunit (see
Results) is henceforth referred to as anti-S1 serum. Rabbit antisera
were prepared against rS3 and rS4 by standard procedures.
Separation of PT components by HPLC.
PTmu was dissociated by
incubation in 5 M cold urea by the procedure of Tamura et al.
(32), which yields products corresponding to the S1 and S5
subunits and the S2-S4 and S3-S4 dimers (32). The
dissociated PTmu (100 µg in 500 µl of 5 M urea) was separated by
high-pressure liquid chromatography (HPLC) using a Spectra Physics
SP8750 HPLC system and a Superdex 75 HR 10/30 gel filtration column
equilibrated with 100 mM phosphate buffer, pH 7.0, containing 25 mM
NaCl. Elution (flow rate, 0.5 ml/min; 264 lb/in2) was
carried out in the same buffer. Protein elution was monitored at 220 nm
with a Waters model 441 detector. The protein concentration was
estimated according to the area of the peaks.
SDS-PAGE and Western blotting.
Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out
according to the procedure of Laemmli (14) on 12% gels
(henceforth referred to as "Laemmli gels") or according to the
procedure of Schägger and von Jagow (27) on 10%
gels (henceforth referred to as "Tricine gels"). All gels were
stained with silver. Western blotting onto nitrocellulose membrane was
carried out according to the procedure of Towbin et al.
(33). Dilutions of 1:500, 1:1,000, 1:8,000, and 1:10,000 were used for anti-S1, anti-S2, anti-S3, and anti-S4 primary antisera, respectively. Reactive bands were detected by enhanced
chemiluminescence (ECL) using an ECL analysis system (catalog no. RPN
2108; Amersham, Amersham, England) according to the manufacturer's protocol.
Slot blot analysis for the presence of PT dimers.
A
glycoprotein binding experiment to assay for the presence
of PT subunits in the form of dimers in the relevant peak was essentially done according to the procedure of Witvliet et al. (37), with minor modifications. Briefly, proteins
resuspended in phosphate-buffered saline (PBS) were applied directly to
nitrocellulose using a Bio-Rad Bio-Dot SF microfiltration apparatus
(catalog no. 170-6542). After blocking for 2 h in bovine serum
albumin (BSA) solution (3% BSA in PBS), the blots were incubated with the various preparations of PT and PT components as indicated in
Results, washed with PBS-Tween (37), and reacted with
anti-S4 serum; binding by anti-S4 serum was detected by ECL as
described above.
In vitro assay of the mitogenic activity of PT and PT components
on naive and committed T cells.
LN cells from naive SJL/J mice
were cultured in microtiter wells (5 × 105
cells/well) as described previously (2), in the presence
of PT, PT components, or concanavalin A (ConA), as indicated. The mitogenic effect of PT and PT components on committed T cells was
tested on mouse line PL/J T cells specific for pMOG35-55, a myelin
oligodendrocyte glycoprotein peptide encompassing amino acids 35 to 55 of the molecule (12). The
pMOG35-55-specific T cells (104 cells/well) were cultured
as described above, in the presence of irradiated (2,500 rads)
syngeneic spleen cells (5 × 105 cells/well) from
naive PL/J mice. The cells were incubated for 72 h (naive LN
cells) or 48 h (pMOG35-55-specific T cells) at 37°C in
humidified air containing 7.5% CO2.
[3H]thymidine (1 µCi/well) was added for the last
16 h of incubation, and the cultures were harvested and counted
using a Matrix 96 Direct beta counter (Packard Instruments, Meriden,
Conn.). The proliferative response was measured as
[3H]thymidine incorporation expressed as mean counts per
minute of triplicate cultures.
Cytofluorometric analysis of T-cell subsets in naive LN cells
stimulated with PTmu, PT components, and other T-cell mitogens.
Naive LN cells (5 × 106 cells/ml) from SJL/J mice
were cultured as described previously (2), in the presence
of PTmu (250 ng/ml), peak II (see Results) (2 µg/ml), ConA (500 ng/ml), or an anti-CD3 monoclonal antibody (MAb) (30 µl of a 1:2
dilution of supernatant from hybridoma hamster anti-mouse CD3, clone
no. 145-2C11, from the American Type Culture Collection). After 2 to 3 days, the cells were split in medium containing interleukin-2. At the
time intervals indicated in Results, the cells were analyzed by
fluorescence-activated cell sorting (FACS) as described previously (17), using the following MAbs: fluorescein isothiocyanate
(FITC)-conjugated anti-mouse TCR
(H57-597; catalog no. 01304D;
Pharmingen, San Diego, Calif.); FITC-conjugated anti-mouse CD8 (YTS
169.4; catalog no. RM2201; Caltag, San Francisco, Calif.), and
phycoerythrin-conjugated anti-mouse CD4 (catalog no. 1447; Becton
Dickinson, Mountain View, Calif.).
Cytofluorometric analysis for apoptosis-necrosis with
annexin.
FACS analysis of apoptotic-necrotic CD4+ and
CD8+ cells was performed by double staining with
FITC-conjugated anti-CD4 (catalog no. 09424D; Pharmingen) or anti-CD8
(as described above) MAb and Annexin-V-Alexa 568 (catalog no. 1985 485;
Boehringer Mannheim/Roche, Mannheim, Germany) according to the
manufacturer's instructions.
Depletion of CD8+ and CD4+ T cells from
naive mice by anti-CD8+ and anti-CD4+
MAbs.
Naive SJL/J mice were injected intraperitoneally on three
consecutive days, 7 to 9 days before in vitro analysis of the mitogenic effect of PT, with a rat anti-mouse CD8+ (YTS-169)
(6) or CD4+ (GK 1-5) (7) MAb (1 ml of a 1:10 dilution of ascites fluid per injection). The hybridomas,
YTS-169 and GK1-5, secreting anti-CD8 and anti-CD4 Abs respectively,
were a kind gift from L. Eisenbach of the Department of Immunology, The
Weizmann Institute of Science. Depletion of the relevant T-cell subsets
was monitored on the day of in vitro culture with PT or mitogens by
FACS analysis of the LN cell population with anti-CD8+ and
anti-CD4+ MAbs as described above; the results obtained
showed full depletion of CD4+ T cells in mice treated with
the anti-CD4 MAb (0.4% CD4+ and 50% CD8+
TCR
+ cells in the LN cell population) and of
CD8+ T cells in mice treated with the anti-CD8 MAb (0.5%
CD8+ and 65% CD4+ TCR
+ cells
in the LN cell population).
 |
RESULTS |
Dissociation of PT components with urea and separation by
HPLC.
Native S2-S4 and S3-S4 dimers can be dissociated from the PT
holomer by incubation of the holomer with 5 M ice-cold urea
(32). To isolate the dimers, PTmu was incubated for 4 days
at 4°C in 0.05 M phosphate buffer (pH 6.0) containing 5 M urea and
the dissociation products were separated by gel filtration on HPLC. As
can be seen on the typical HPLC elution profile presented in Fig.
1A, three protein peaks were eluted,
which were further analyzed for PT components and the presence of
dimers.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 1.
Fractionation of urea-dissociated PT by HPLC. Panels A,
chromatographic profile; B, silver-stained 10% Tricine gel of PT and
peaks I through III (protein amounts loaded: PT, 4 µg; peak I, 1 µg; peak II, 1.5 µg; peak III, 1.5 µg); C, electrophoresis
profiles of PTmu on Tricine and Laemmli gels (lanes a) and
corresponding Western blots (lanes b) indicating that the S3 subunit
migrates as a doublet on Tricine gels but not on Laemmli gels. Lanes a
are silver-stained gels, and lanes b are the corresponding Western
blots probed with anti-S3 serum. Rabbit anti-S3 serum was used at a
dilution of 1:8,000, and reactive bands were detected by ECL. Two
micrograms of PTmu was loaded on the gels. OD, optical density.
|
|
Characterization of HPLC gel filtration peaks: isolation of S3-S4
dimer. (i) SDS-PAGE.
Because of its greater power of separation,
the Tricine SDS-PAGE method of Schägger and von Jagow
(27) was used to analyze the HPLC fractions obtained from
the dissociated PT (Fig. 1B). Although PT migrates as five bands in the
Laemmli (14) SDS-PAGE system (32) (Fig. 1C),
an additional band running close to the S3 subunit could be observed on
a 10% Tricine gel (Fig. 1C). Interestingly, the S3 subunit was
demonstrated by Western blotting with a highly specific anti-S3 Ab (see
below) to run as a doublet in this gel system but not on a 12% Laemmli
gel (Fig. 1C). The significance of this observation is unclear. The
electrophoretic pattern of peak I on the 10% Tricine gel (Fig. 1B) was
similar to that of undissociated PT, except that the density of the
band corresponding in molecular size to S1 was decreased, suggesting
that peak I represents a mixture of the B oligomer and whole PT. A
doublet corresponding to S3 and one band corresponding to S4 were seen in peak II (Fig. 1B). Peak III contained very small amounts of protein.
Upon concentration, most of the protein aggregated (Fig. 1B).
To ascertain the presence or absence of different subunits in peaks I
and II, rabbit or mouse polyclonal Abs were raised against preparations
of rS2, rS3, and rS4 and components of the peaks were analyzed by
Western blotting.
(ii) Western blotting.
The specificity of the polyclonal Abs
to be used was determined by Western blotting of native subunits of
PTmu and of the recombinant proteins used for Ab production. The
Laemmli SDS-PAGE system (14) was used throughout in
Western blotting analyses to ascertain Ab specificity and to determine
the composition of the HPLC fractions. On SDS-PAGE, rS2, rS3, and rS4
migrated with slightly higher molecular weights than the native
subunits, due to the His tag added to enable purification of the
recombinant proteins by nickel affinity chromatography. As can be seen
in Fig. 2, single bands reacted when
native PT was analyzed with anti-S2 (Fig. 2A), anti-S3 (Fig. 2B), and
anti-S4 (Fig. 2C) Abs, respectively, indicating that despite the high
degree of homology between S2 and S3 (19), the Abs raised
recognize the native subunits in a highly specific manner and can be
used to analyze the HPLC peaks for the presence or absence of the
various subunits. A slight cross-reactivity was observed when the Abs
were tested against the recombinant subunits. Such cross-reactivity,
observed mainly with the anti-S2 and anti-S4 Abs (see also below), is
likely to be due to the presence, within the polyclonal antisera, of Abs which react to the common His tag portion of the recombinant proteins used for immunization. The presence of S1 was tested with a
mouse anti-PT serum which had shown a predominant high reactivity to S1
(see below).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Western blot analysis of the specificity of Abs raised
to rS2, rS3, and rS4. rS2, rS3, and rS4 (0.5 µg/lane) and PTmu (1 µg/lane), electrophoresed on a 12% Laemmli gel and Western blotted
onto nitrocellulose, were reacted with anti-S2 serum (dilution, 1:500;
panel A), anti-S3 serum (dilution, 1:10,000, panel B), or anti-S4 serum
(dilution, 1:10,000; panel C), and reactive bands were detected by
ECL.
|
|
According to the electrophoretic profile, it is likely that peak II
contains only S3 and S4, possibly in the form of a dimer. To ascertain
the presence of S3, peak II, along with PTmu and peak I, was analyzed
by Western blotting with anti-S3 serum (Fig. 3A). Reaction of a single band migrating
at the same position in all three samples confirmed the presence of S3
in peak II, as well as in peak I. The same blot was then reprobed with
anti-S2 serum to eliminate the possibility that small amounts of S2,
undetectable on the silver-stained gel, were present in peak II. As can
be seen in Fig. 3B, reactivity with the anti-S2 serum could not be detected in peak II. In contrast, anti-S2-reactive bands were revealed
in the lanes containing PTmu and peak I, where the amounts of protein
electrophoresed were smaller than that of peak II (Fig. 3B). Subsequent
probing of the same blot with anti-S4 serum revealed a band
corresponding to the S4 subunit in peak II as well as peak I (Fig. 3C),
confirming the detection of S4 on the silver-stained gel (Fig. 1B).
Immunoblot analysis with anti-S1 serum of peaks I and II, compared to
gel-purified S1 and PT, indicated that while a strong reaction was
observed with the purified S1 and a band migrating with the same
molecular weight in the PT preparation, such reactivity could be
observed neither with peak I nor with peak II (Fig.
4). Altogether, these data indicated that
peak II is composed of the S3 and S4 subunits whereas peak I also
contains S2 and S5 and may represent the undissociated B oligomer of
PT. Whether or not the S3 and S4 subunits were present in peak II in
the form of a dimer was assessed using the blot assay devised by
Witvliet et al. (37).

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 3.
Western blot analysis of peak II components by
sequential probing with specific Abs. PTmu (1 µg) and peaks I (1 µg) and II (1.5 µg) from the HPLC fractionation of PTmu were
electrophoresed on a 12% Laemmli gel and Western blotted onto
nitrocellulose. The blot was then sequentially probed with anti-S3
serum (dilution, 1:10,000; panel A), anti-S2 serum (dilution, 1:500;
panel B), and anti-S4 serum (dilution, 1:10,000; panel C). Reactive
bands were detected by ECL after each probing.
|
|

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 4.
Western blot analysis for the presence of S1 in peaks I
and II. S1 (approximately 100 ng), purified by preparative gel elution
as described previously (3), and PT (1 µg), peak I (1 µg), and peak II (0.5 µg), electrophoresed on a 12% Laemmli gel
and Western blotted, were reacted with anti-S1 serum (dilution,
1:1,000). The reactive bands were detected by ECL.
|
|
(iii) Slot blot analysis for dimer binding to
glycoprotein.
The assay of Witvliet et al.
(37) is based on the well-known property of PT, or the
S2-S4 and S3-S4 dimers, to bind glycoproteins, in
particular, fetuin and haptoglobin, via the S2 or S3 subunit, both of
which have a lectin-like property (26, 31). Purified glycoproteins are blotted onto nitrocellulose and reacted
with the PT preparations, and the bound dimers are detected by
recognition of the S4 subunit with an anti-S4 serum (37).
This assay was adapted to determine whether the S3 and S4 subunits
comprising peak II were present as a dimer. The slot blots to be
reacted contained the relevant purified glycoproteins;
fetuin and haptoglobin; ovalbumin (OVA) and BSA as negative controls;
and rS2, rS3, and rS4 (Fig. 5).
Incubation of the blots with PT, followed by anti-S4 serum, confirmed
the ability of PT to bind to haptoglobin and fetuin (Fig. 5); rS4
reacted strongly with the anti-S4 serum (a slight reactivity of the
anti-S4 serum with rS2 and rS3 was observed as noted above). No
reactivity with OVA or BSA could be detected. When the blots were
probed with peak II containing S3 and S4, a pattern of reactivity
identical to that of blots probed with PT was observed (Fig. 5),
indicating that peak II contains the S3 and S4 subunits as a dimer
which binds to fetuin and haptoglobin via the S3 subunit and is
detected by antigen-antibody recognition of the S4 subunit. The lower
intensity of binding to fetuin by the S3-S4 dimer compared to PT is
related to the presence of the S2-S4 dimer in PT and its absence in
peak II, as the S2-S4 dimer has a stronger affinity for fetuin than
does the S3-S4 dimer (37). That the S4 subunit by itself
does not bind to fetuin or haptoglobin and therefore could not be
responsible for the pattern observed with peak II is demonstrated in
the blot probed with the rS4 subunit and the anti-S4 Ab, which
displayed a pattern commensurate only with reactivity of the anti-S4 Ab
with rS4 (Fig. 5); no reactivity could be observed with fetuin,
haptoglobin, OVA, or BSA.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 5.
The S3 and S4 subunits are present in peak II in the
form of a dimer. Fetuin (1 µg), haptoglobin (1 µg), OVA (1 µg),
BSA (1 µg), and rS2, rS3, and rS4 (0.5 µg of each) were adsorbed
onto nitrocellulose using a Bio-Rad Bio-Dot SF microfiltration
apparatus. The slot blots were incubated with PTmu (2 µg/ml), peak II
(2 µg/ml), or rS4 (2 µg/ml), as indicated. Binding of dimers within
the preparations was detected by reaction of the slot blots with
anti-S4 serum (dilution, 1:10,000) developed with ECL. Binding to
fetuin by the S3-S4 dimer is weaker than to haptoglobin
(37). Accordingly, the band of peak II reactivity to
fetuin is faint, albeit highly reproducible.
|
|
The S3-S4 dimer is mitogenic for T cells.
The mitogenic effect
of PT is known to reside with the B oligomer (9, 31, 36).
In a preliminary attempt to investigate the possibility that such
mitogenic activity of the B oligomer involves the S3-S4 dimer, the
effect of peak II on naive and committed T cells was assessed, compared
to the effects of PTmu, the B oligomer, rS2, rS3, and rS4. As can be
seen in Fig. 6, culture of naive LN cells
from SJL/J mice in the presence of 250 ng of PT or the B oligomer
resulted in extensive proliferation; the same amount of peak I or peak
II induced an even stronger response, commensurate with the
proliferative response to the T-cell mitogen ConA. Naive LN cells did
not proliferate in response to 250 ng of rS2, rS3, or rS4 (Fig. 6) or
in response to lower concentrations (50 and 100 ng/well) of the
individual recombinant subunits (data not shown).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 6.
The S3-S4 dimer of PT is mitogenic for naive and
committed T cells. Cells were cultured as described in Materials and
Methods with PT, the B oligomer, peak I, peak II, rS2, rS3, or rS4 (250 ng/well); ConA (100 ng/well); or pMOG35-55 (1 µg/well). The
stimulation index (in parentheses) was calculated as the mean
stimulation in the presence of the relevant protein preparation divided
by the mean stimulation in the absence of the added protein (None).
n.t., not tested; n.a., not applicable; SD, standard deviation.
|
|
The mitogenic effects of PTmu, peak I, and peak II could also be
observed with PL/J line CD4+ T cells highly specific for
pMOG35-55 (Fig. 6), a myelin oligodendrocyte glycoprotein
peptide (12). The pMOG35-55-specific T cells proliferated to the same extent in response to peak II as in response to peak I or
PTmu, and such mitogenic proliferation was as strong as the antigenic
proliferation of the T cells in response to the peptide (Fig. 6). The
pMOG35-55-specific T-cells did not proliferate in the presence of any
of the recombinant subunits. The mitogenic effect of peaks I and II on
T cells was dose dependent, reaching a plateau at a mitogen
concentration of 500 ng/well (data not shown).
Reversal of the CD4+/CD8+ T-cell ratio upon
stimulation of naive LN cells with the S3-S4 dimer, as well as
PTmu.
LN cells isolated from naive SJL/J mice were cultured (5 × 106 cells/ml) for 96 h in the presence of PTmu (250 ng/ml), the S3-S4 dimer (peak II) (2 µg/ml), ConA (500 ng/ml), or the
anti-CD3 MAb (30 µl of a 1:2 dilution of culture supernatant/ml), and
the proportion of TCR
+ T cells which expressed
CD4+, CD8+, or CD4+
CD8+ was estimated by FACS analysis. As can be seen in
Table 1, the ratio of CD4+ to
CD8+ T cells in the TCR
+ LN cell
population which were stimulated in vitro with ConA or the anti-CD3 MAb
(53 and 44% CD4+ and 21 and 20% CD8+) did not
differ significantly from the ratio of CD4+ to
CD8+ T cells estimated in naive TCR
+
cells (50% CD4+ and 28.5% CD8+), indicating
that ConA and the anti-CD3 MAb have a nondiscriminatory mitogenic
effect on T cells. In contrast, the proportions of CD8+ T
cells and CD4+ T cells changed dramatically following
stimulation with PTmu (Table 1), resulting in a complete reversal of
the CD4+/CD8+ ratio (19.9% CD4+
and 65.9% CD8+). A similar reversal of the
CD4+/CD8+ ratio was obtained upon stimulation
with native PT or with the B oligomer (data not shown). As shown in
Table 1, stimulation of naive LN cells with the S3-S4 dimer (peak II)
also resulted in reversal of the CD4+/CD8+
ratio (24% CD4+ and 58.2% CD8+), indicating
that the mitogenic S3-S4 dimer is sufficient to reproduce the effect of
PTmu on the CD4+/CD8+ ratio. Similar results
were obtained whether interleukin-2 was present or not for the last 2 to 3 days of culture (data not shown). To further assess the effect of
PT and the S3-S4 dimer on T-cell subsets, the proportions of
CD4+ and CD8+ T cells in naive LN cells were
determined by FACS analysis at various intervals during incubation with
PTmu, the S3-S4 dimer, the anti-CD3 MAb, and ConA. As can be seen
in Fig. 7, an increase in the
proportion of CD8+ T cells, in parrallel with a decrease in
the proportion of CD4+ T cells, was observed upon
incubation with PTmu or with the S3-S4 dimer; the extent of the
reversal of the CD4+/CD8+ ratio peaked after
approximately 72 h of incubation and leveled out thereafter (Fig.
7). The proportion of CD4+ or CD8+ T cells did
not change at any time during incubation with the anti-CD3 MAb or ConA
(Fig. 7). The reversal of the CD4+/CD8+ ratio
in naive LN cells incubated with PTmu or the S3-S4 dimer does not
appear to be due to preferential stimulation of CD8+ T
cells by PTmu or the S3-S4 dimer; indeed, the extent of proliferation in response to PTmu, as standardized to the proliferation in response to the anti-CD3 MAb, did not differ between LN cells isolated from mice
fully depleted of CD8+ T cells by treatment with the
anti-CD8 MAb and LN cells isolated from mice fully depleted of
CD4+ T cells by treatment with the anti-CD4 MAb (Fig.
8). To assess the possibility that the
increase in the proportion of CD8+ T cells upon stimulation
with PT or the S3-S4 dimer was a result of preferential
apoptosis-necrosis of CD4+ T cells, LN cells from naive
mice and from mice depleted of CD8+ or CD4+ T
cells were stimulated with PTmu, the anti-CD3 MAb, or ConA and analyzed
by FACS for annexin staining at various intervals during a 5-day
culture. FACS analysis of cells double stained with annexin and the
anti-CD4 or anti-CD8 MAb did not indicate any preferential
apoptosis-necrosis of CD4+ T cells over CD8+ T
cells in naive LN cells incubated with PTmu (Fig.
9, Undepleted), nor was there any
difference in the extent of apoptosis-necrosis in the naive LN cells
incubated with the anti-CD3 MAb or ConA, compared with the PTmu
incubation (Fig. 9, Undepleted). These observations were corroborated
by data obtained with LN cells from CD4+ T-cell-depleted or
CD8+ T-cell-depleted mice (Fig. 9); indeed, the extent of
apoptosis-necrosis of the T cells was essentially the same in cultures
stimulated with PTmu, the anti-CD3 MAb, or ConA, regardless of the
origin of the LN cells (Fig. 9).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
In vitro stimulation of naive LN cells with PTmu or the
S3-S4 dimer results in reversal of the
CD4+/CD8+ T-cell ratioa
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Time course analysis of reversal of the
CD4+/CD8+ T-cell ratio upon in vitro
stimulation of naive LN cells with PT and the S3-S4 dimer (peak II).
Naive LN cells were cultured as described in Materials and Methods in
the presence of the indicated mitogens. At the time intervals
indicated, 0.2 × 106 cells were tested for CD4 and
CD8 expression by double-staining FACS analysis. The data shown are
means ± standard deviations of three separate experiments. An
asterisk indicates CD4+ or CD8+ cells among
TCR + cells.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 8.
Reversal of the CD4+/CD8+ ratio
in LN cells stimulated with PTmu is not due to preferential stimulation
of CD8+ T cells. The proliferative response to the anti-CD3
Ab (5 µl/ml) or PTmu (250 ng/ml) by LN cells isolated from normal
mice, mice depleted of CD4+ T cells, or mice depleted of
CD8+ T cells was assayed as described in Materials and
Methods and is expressed as a mean stimulation index (SI) ± the
standard deviation (SD). Standardization of PTmu stimulation to
anti-CD3 Ab stimulation equals 0.85, 0.77, and 1.02 for normal,
CD4-depleted, and CD8-depleted mice, respectively.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 9.
Time course analysis of apoptosis-necrosis in
CD4+ and CD8+-expressing cells upon in vitro
stimulation with different mitogens of LN cells from naive
(Undepleted), CD4+ T-cell-depleted, and CD8+
T-cell-depleted mice. LN cells from naive (Undepleted),
CD4+ T-cell-depleted, and CD8+ T-cell-depleted
mice were cultured as described in Materials and Methods in the
presence of PTmu, the anti-CD3 MAb and ConA. At the time intervals
indicated, 0.2 × 106 cells were tested by
double-staining FACS analysis for the proportion of CD4+ or
CD8+ apoptotic-necrotic T cells in the cultures. The mean
data of three experiments are shown for each time point; the standard
deviation (not shown) varied between 5 and 15% of the mean. An
asterisk indicates the percentage of CD4+ or
CD8+ T cells which were also stained with annexin.
|
|
 |
DISCUSSION |
The data presented in this report provide direct evidence that the
S3-S4 dimer of PT is mitogenic and suggest, moreover, that the S3-S4
dimer would be sufficient to account for the mitogenic activity of the
B oligomer. To the best of our knowledge, this study is also the first
to demonstrate that in vitro stimulation with PT or its S3-S4 dimer
component, of naive cells derived from a mature lymphoid organ, results
in a reversal of the CD4+/CD8+ T-cell ratio.
The best-described property of the B oligomer is its mitogenic
activity; the catalytic subunit S1 does not play a role in the
mitogenicity of PT, as PTmu was as strongly mitogenic as the B oligomer
(13; this study). Some of the biological effects and biochemical
properties of the B oligomer have been shown to be more strongly
associated with the S2-S4 or S3-S4 heterodimer of PT, rather than with
the S2 or S3 subunit alone, suggesting that conformation of the subunit
as a dimer with S4 is important for activity. Along these lines, we
observed a very strong mitogenic effect of the isolated S3-S4 dimer
(peak II), on both naive and committed antigen-specific T cells,
whereas the recombinant subunits had no such effect. These results are
in contrast to previous reports indicating that the S2-S4 and S3-S4
dimers are not mitogenic by themselves (31, 36). The only
obvious difference between our study and those previously reported
(31, 36) is the absence of urea in our S3-S4 dimer
preparation. The possibility that the mitogenic activity of peak II is,
in fact, due to contamination with small amounts of the S2-S4 dimer,
and therefore to divalent binding on T cells by the S2-S4 and S3-S4
dimers, is highly unlikely, as S2 could not be detected by very
sensitive Western blotting of relatively large amounts of peak II,
where S3 and S4 appear as very strongly reacting, broad bands. It is
more likely that an appropriate conformation of the S3-S4 dimer is
necessary for mitogenic activity. Hence, the previous failure to
demonstrate the mitogenic activity of the dimer itself may be due
simply to the fact that all previous attempts were performed with
dimers that were isolated and stored in urea and therefore did not
present an appropriate conformation for the biological activity.
Isolation of the S3-S4 dimer in the absence of urea in our study would
have allowed adequate refolding of the dimer. It is highly relevant to
point out the circumstantial evidence suggesting that the S3-S4 dimer
is most likely implicated in the mitogenicity of the B oligomer, whereas the S2-S4 dimer may only play a more minor role in this function. Studies have used methylated PT to analyze the involvement of
the various PT components in the biological activity of PT (20,
21). Chemical modification of PT by methylation of lysine residues does not significantly interfere with the A
protomer-transporting activity of the B oligomer but results in loss of
the mitogenic activity of PT (21). Subsequent studies with
hybrid, differentially methylated PT holomers indicated that the two
dimers play differential roles in the mitogenic activity of the B
oligomer; thus, hybrid PT formed with a methylated S3-S4 dimer lost its
ability to stimulate T lymphocytes, whereas hybrid PT formed with a
methylated S2-S4 dimer was as potent a mitogen as unmodified PT
(22). Unfortunately, the direct role of the S2-S4 dimer
could not be evaluated in our study, as we were not able to purify the
S2-S4 dimer under the chromatography conditions used, possibly as a
result of its strong binding to Sephadex.
How stimulation by PT or the S3-S4 dimer results in reversal of the
CD4+/CD8+ T-cell ratio is unclear. From our
data, it does not appear to be a result of preferential
CD4+ T-cell death or preferential stimulation of
CD8+ T cells. Recent studies suggest the possibility that
PTmu or the S3-S4 dimer can selectively induce the generation of
CD8+ T cells from CD4+ CD8+ T-cell
precursors. Thus, using ZAP-70
mutant thymus organ
cultures in which T-cell development is arrested at the
CD4+ CD8+ thymocyte stage, Takahama et al.
(30) showed that PT or, more specifically, the B oligomer
selectively induced the generation of CD4
CD8+ TCRhigh cells, possibly by up-regulating
Notch expression (30). Notch has been implicated as a
participant in the CD4 versus CD8 lineage decision, whereby expression
of an activated form of Notch in developing murine T cells was
demonstrated to lead to both an increase in CD8 lineage T cells and a
decrease in CD4 lineage T cells (25). It is interesting
that an increase in the proportion of CD8+ T cells was also
observed in ex vivo LN cells obtained from mice injected with PT (our
unpublished results) and similar observations of sustained increases in
CD8+ T-cell levels were noted in rhesus macaques as long as
53 days after PT injection (23). The possibility that in
vitro PT or the S3-S4 dimer may act on CD4+
CD8+ T cells to preferentially induce differentiation into
CD8+ T cells is being further investigated.
Hence, we have demonstrated that the mitogenic activity of PT does not
necessarily require the whole B oligomer or divalent binding by the
S2-S4 and S3-S4 heterodimers, as shown previously, but that the S3-S4
heterodimer alone can be fully functional in stimulating T cells. In
addition, in contrast to other T-cell mitogens, PT or the S3-S4 dimer
may exert an immunomodulating effect on the T-cell population by
stimulating an increase in the overall proportion of CD8+ T
cells. We are considering this aspect further in the context of our
investigation of the protective effect of PT on autoimmune diseases
such as EAE (3, 4).
 |
ACKNOWLEDGMENTS |
This work was partially supported by the Minerva Foundation,
Munich, Germany. A. Ben-Nun is the incumbent of the Eugene and Marcia
Appelbaum Professorial Chair.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dept. of
Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel.
Phone: 972-8-9342991. Fax: 972-8-9344141. E-mail:
lcbennun{at}wicc.weizmann.ac.il.
This paper is dedicated to Tany Amarant, who passed away suddenly
on 6 March 2000.
Present address: Mount Sinai Medical Center, New York, NY 10128.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Bartley, T. D.,
D. W. Whiteley,
V. L.,
D. L. Mar Burns, and W. N. Burnette.
1989.
Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit.
Proc. Natl. Acad. Sci. USA
86:8353-8357[Abstract/Free Full Text].
|
| 2.
|
Ben-Nun, A., and Z. Lando.
1983.
Detection of cells responding to myelin basic protein by proliferation and selection of T cell lines functional in mediating experimental autoimmune encephalomyelitis in mice.
J. Immunol.
130:1205-1209[Abstract].
|
| 3.
|
Ben-Nun, A.,
I. Mendel, and N. Kerlero de Rosbo.
1997.
Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: the protective activity, but not the disease-enhancing activity, can be attributed to the nontoxic B-oligomer.
Proc. Assoc. Am. Phys.
109:120-125[Medline].
|
| 4.
|
Ben-Nun, A.,
S. Yossefi, and D. Lehman.
1993.
Protection against autoimmune disease by bacterial agents. II. PPD and pertussis toxin as proteins active in protecting mice against experimental autoimmune encephalomyelitis.
Eur. J. Immunol.
23:689-696[Medline].
|
| 5.
|
Black, W. J.,
J. J. Munoz,
M. J. Peacock,
P. A. Schad,
J. L. Cowell,
J. J. Burchall,
M. Lim,
A. Kent,
L. Steinman, and S. Falkow.
1988.
ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis.
Science
240:656-659[Abstract/Free Full Text].
|
| 6.
|
Cobbold, S. P.,
A. Jayasuriya,
A. Nash,
T. D. Prospero, and H. Waldmann.
1984.
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.
Nature (London)
312:548-551[CrossRef][Medline].
|
| 7.
|
Dialynas, D. P.,
Z. S. Quan,
K. A. Wall,
A. Pierres,
J. Quintans,
M. R. Loker,
M. Pierres, and F. W. Fitch.
1983.
Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.
J. Immunol.
131:2445-2451[Abstract].
|
| 8.
|
Gierschik, P.
1992.
ADP-ribosylation of signal-transducing guanine nucleotide-binding proteins by pertussis toxin.
Curr. Top. Microbiol. Immunol.
175:69-96[Medline].
|
| 9.
|
Gray, L. S.,
K. S. Huber,
M. C. Gray,
E. L. Hewlett, and V. H. Engelhard.
1989.
Pertussis toxin effects on T lymphocytes are mediated through CD3 and not by pertussis toxin catalyzed modification of a G protein.
J. Immunol.
142:1631-1638[Abstract].
|
| 10.
|
Hausman, S. Z., and D. L. Burns.
1993.
Binding of pertussis toxin to lipid vesicles containing glycolipids.
Infect. Immun.
61:335-337.
|
| 11.
|
Heerze, L. D.,
P. C. S. Chong, and G. D. Armstrong.
1992.
Investigation of the lectin-like binding domains in pertussis toxin using synthetic peptide sequences.
J. Biol. Chem.
267:25810-25815[Abstract/Free Full Text].
|
| 12.
|
Kerlero de Rosbo, N.,
I. Mendel, and A. Ben-Nun.
1995.
Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes.
Eur. J. Immunol.
25:985-993[Medline].
|
| 13.
|
Kimura, A.,
K. T. Mountzouros,
P. A. Schad,
W. Cieplak, and J. L. Cowell.
1990.
Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.
Infect. Immun.
58:3337-3347[Abstract/Free Full Text].
|
| 14.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (London)
227:680-685[CrossRef][Medline].
|
| 15.
|
Lobet, Y.,
C. Feron,
G. Dequesne,
E. Simoen,
P. Hauser, and C. Locht.
1993.
Site-specific alterations in the B-oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin.
J. Exp. Med.
177:79-87[Abstract/Free Full Text].
|
| 16.
|
Loosmore, S.,
G. Zealey,
S. Cockle,
H. Boux,
P. Chong,
R. Yacoob, and M. Klein.
1993.
Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits.
Infect. Immun.
61:2316-2324[Abstract/Free Full Text].
|
| 17.
|
Mendel, I.,
N. Kerlero de Rosbo, and A. Ben-Nun.
1995.
A myelin-oligodendrocyte glycoprotein (MOG) peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice. Fine specificity and T cell receptor Vb expression of encephalitogenic T cells.
Eur. J. Immunol.
25:1951-1959[Medline].
|
| 18.
|
Munoz, J. J.
1985.
Biological activities of pertussigen (pertussis toxin), p. 1-18.
In
R. D. Sekura, J. Moss, and M. Vaughan (ed.), Pertussis toxin. Academic Press, Inc., New York, N.Y.
|
| 19.
|
Nicosia, A.,
A. Bartoloni,
M. Perugini, and R. Rappuoli.
1987.
Expression and immunological properties of the five subunits of pertussis toxin.
Infect. Immun.
55:963-967[Abstract/Free Full Text].
|
| 20.
|
Nogimori, K.,
K. Ito,
M. Tamura,
S. Satoh,
S. Ishii, and M. Ui.
1984.
Chemical modification of islet-activating protein, pertussis toxin. Essential role of free amino groups in its lymphocytosis-promoting activity.
Biochim. Biophys. Acta
801:220-231[Medline].
|
| 21.
|
Nogimori, K.,
M. Tamura,
M. Yajima,
K. Ito,
T. Nakamura,
N. Kajikawa,
Y. Maruyama, and M. Ui.
1984.
Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modifications of lysine residues in the toxin molecule.
Biochim. Biophys. Acta
801:232-243[Medline].
|
| 22.
|
Nogimori, K.,
M. Tamura,
M. Yajima,
N. Hashimura,
S. Ishii, and M. Ui.
1986.
Structure-function relationship of islet-activating protein, pertussis toxin: biological activities of hybrid toxins reconstituted from native and methylated subunits.
Biochemistry
25:1355-1363[CrossRef][Medline].
|
| 23.
|
Pauza, C. D.,
P. W. Hinds,
C. Yin,
T. S. McKechnie,
S. B. Hinds, and M. S. Salvato.
1997.
The lymphocytosis-promoting agent pertussis toxin affects virus burden and lymphocyte distribution in the SIV-infected rhesus macaque.
AIDS Res. Hum. Retrovir.
13:87-95[Medline].
|
| 24.
|
Pizza, M.,
A. Covacci,
A. Bartoloni,
M. Perugini,
L. Nencioni,
M. T. De Magistratis,
L. Villa,
D. Nucci,
R. Manetti,
M. Bugnoli,
F. Giovanni,
R. Olivieri,
J. T. Barbieri,
H. Sato, and R. Rappuoli.
1989.
Mutants of pertussis toxin suitable for vaccine development.
Science
246:497-500[Abstract/Free Full Text].
|
| 25.
|
Robey, E.,
D. Chang,
A. Itano,
D. Cado,
H. Alexander,
D. Lans,
G. Weinmaster, and P. Salmon.
1996.
An activated form of Notch influences the choice between CD4 and CD8 T cell lineages.
Cell
87:483-492[CrossRef][Medline].
|
| 26.
|
Saukkonen, K.,
W. N. Burnette,
V. L. Mar,
H. R. Masure, and E. I. Tuomanen.
1992.
Pertussis toxin has eukaryotic-like carbohydrate recognition domains.
Proc. Natl. Acad. Sci. USA
89:118-122[Abstract/Free Full Text].
|
| 27.
|
Schägger, H., and G. von Jagow.
1987.
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.
Anal. Biochem.
166:368-379[CrossRef][Medline].
|
| 28.
|
Stein, P. E.,
A. Boodhoo,
G. D. Armstrong,
S. A. Cockle,
M. H. Klein, and R. J. Read.
1994.
The crystal structure of pertussis toxin.
Structure
2:45-57[Medline].
|
| 29.
|
Strnad, C., and R. A. Carchman.
1987.
Human T lymphocyte mitogenesis in response to the B oligomer of pertussis toxin is associated with an early elevation in cytosolic calcium concentrations.
FEBS Lett.
223:16-20.
|
| 30.
|
Takahama, Y.,
Y. Tokoro,
T. Sugawara,
I. Negishi, and H. Nakauchi.
1997.
Pertussis toxin can replace T cell receptor signals that induce positive selection of CD8 T cells.
Eur. J. Immunol.
27:3318-3331[Medline].
|
| 31.
|
Tamura, M.,
K. Nogimori,
M. Yajima,
K. Ase, and M. Ui.
1983.
A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells.
J. Biol. Chem.
258:6756-6761[Abstract/Free Full Text].
|
| 32.
|
Tamura, M.,
K. Nogimori,
S. Murai,
M. Yajima,
K. Ito,
T. Katada,
M. Ui, and S. Ishii.
1982.
Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.
Biochemistry
21:5516-5522[CrossRef][Medline].
|
| 33.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 34.
|
van't Wout, J.,
W. N. Burnette,
V. L. Mar,
E. Rozdzinski,
S. D. Wright, and E. I. Tuomanen.
1992.
Role of carbohydrate recognition domains of pertussis toxin in adherence of Bordetella pertussis to human macrophages.
Infect. Immun.
60:3303-3308[Abstract/Free Full Text].
|
| 35.
|
Weiss, A. A., and E. L. Hewlett.
1986.
Virulence factors of Bordetella pertussis.
Annu. Rev. Microbiol.
40:661-686[CrossRef][Medline].
|
| 36.
|
Witvliet, M. H.,
M. L. Vogel,
E. J. H. J. Wiertz, and J. T. Poolman.
1992.
Interaction of pertussis toxin with human T lymphocytes.
Infect. Immun.
60:5085-5090[Abstract/Free Full Text].
|
| 37.
|
Witvliet, M. H.,
D. L. Burns,
M. J. Brennan,
J. T. Poolman, and C. R. Manclark.
1989.
Binding of pertussis toxin to eucaryotic cells and glycoproteins.
Infect. Immun.
57:3324-3330[Abstract/Free Full Text].
|
Infection and Immunity, May 2001, p. 3073-3081, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.3073-3081.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lapenta, C., Spada, M., Santini, S. M., Racca, S., Dorigatti, F., Poli, G., Belardelli, F., Alfano, M.
(2005). Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. Int Immunol
17: 469-475
[Abstract]
[Full Text]
-
Weiss, A. A., Patton, A. K., Millen, S. H., Chang, S.-J., Ward, J. I., Bernstein, D. I.
(2004). Acellular Pertussis Vaccines and Complement Killing of Bordetella pertussis. Infect. Immun.
72: 7346-7351
[Abstract]
[Full Text]
-
Millen, S. H., Bernstein, D. I., Connelly, B., Ward, J. I., Chang, S.-J., Weiss, A. A.
(2004). Antibody-Mediated Neutralization of Pertussis Toxin-Induced Mitogenicity of Human Peripheral Blood Mononuclear Cells. Infect. Immun.
72: 615-620
[Abstract]
[Full Text]